Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).

Among them, the responder group exhibited increased activation of the pathways regarding interleukin signaling ( figure 4A ) and ERBB2/3 ( figure 4B ) with marginal significance (p=0.05 and p=0.493, respectively).

also in 1,474 other papers